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genitourinary (GU) and/or gastrointestinal (GI) late toxicity with p = 
0.0043 after Bonferroni correction in a recessive SNP model. This SNP 
belongs to BBC3/PUMA that plays a critical role in DNA damage-
induced apoptosis. EPIC-validated quality-of-life questionnaires were 
surveyed for these patients with a maximum follow-up of 5 years. In 
this study, we further tested the relationship between rs2032809 and 
EPIC scores (sexual function [SF], sexual bother [SB], and sexual 
domain summary [SS]).  
Results: At baseline, the mean SF, SB, and SS scores were 44.63 (95% 
confidence level [CI]: 39.53 – 49.45), 63.52 (95% CI: 58.20 – 69.13), 
and 50.40 (95% CI: 45.43 – 55.03), respectively. At 5-year follow-up, 
the mean SF, SB, and SS scores decreased by 41%, 30%, and 40%, 
respectively. A Mann-Whitney U test was used to investigate 
relationship between rs2032809 and EPIC scores. Significant 
associations were found with third-year SB (p = 0.039) and SS (p = 
0.037) scores (Figure 1). In the third year, the mean SB scores for 
those who have and do not have the minor allele were 71.53 and 
44.49, and 50.33 and 31.47 for the mean SS score, respectively, 
suggesting a considerable protective effect of this SNP. An additional 
test between the SNP and a fifth-year SF score yielded a borderline 
significant estimate (p = 0.090) and the mean SF scores were 45.76 
and 23.85, respectively, for those who have and do not have the 
minor allele.  
 
 Figure 1. Comparison of mean EPIC scores (+standard error of the 
mean) for patients who have GG+GA and AA genotypes in rs2032809 
using Mann-Whitney U test. SF: sexual function; SB: sexual bother; SS: 
sexual domain summary. 
Conclusions: We further examined a single BBC3/PUMA gene SNP 
(rs2032809) that was identified as a candidate biomarker of GI/GU 
toxicity in prostate cancer patients with a hypothesis as to whether 
this SNP is also correlated with sexual dysfunction. We observed a 
statistically significant association between the SNP and the third or 
fifth-year ED of patients. This further strengthens the evidence that 
this apoptosis gene is an important determinant of late toxicity and is 
affected by rs2032809.  
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Purpose/Objective: The aim of this study is to compare the 
protective effect of melatonin and amifostine on radiation induced 
acute renal damage.  
Materials and Methods: Fifty female albino rats were divided into five 
groups (with ten rats each): control (Cont), radiotherapy alone (RT), 
radiotherapy + amifostine (RT+AMI), radiotherapy + melatonin 
(RT+MEL), radiotherapy + amifostine + melatonin (RT+AMI+MEL). All 
experiments were conducted adhering to the guidelines of the 
institutional animal ethics committee. RT group were treated with 
only 0.9% saline solution 30 min before irradiation. Intraperitoneal 
amifostine (200 mg/kg) was administered to the rats in the RT+AMI 
and RT+AMI+MEL groups 30min before irradiation. Intraperitoneal 
melatonin (100 mg/kg) was administered to the rats in the RT+MEL 
and RT+AMI+MEL groups 30 min before irradiation. RT, RT+AMI, 
RT+MEL and RT+AMI+MEL groups were irradiated individually with a 
single dose of 8 Gy on whole body, using a Co-60 treatment unit 
(Cirus,cis-BioInt., Gif-sur-Yvette,France). Dose rate was 1.15 Gy/min. 
At the end of the follow-up period (72 hours) sacrification was done in 
all groups. Paraffin embedded kidney tissue samples were analyzed 
and percentage of damaged glomeruli was determined by counting 
damaged glomeruli of kidney cortex as segmental or total necrosis for 
each animal. 
Results: The percentage of damaged glomeruli is presented in Table 
1. The protective effectof amifostine, melatonin, and amifostin plus 
melatonin on radiation induced renal toxicity is statistically 
meaningful (p 0.000, 0.003, 0.000, respectively). There is an 
advantage in favor of melatonin when compared with amifostine (p 
0.005). Although there is not an advantage of adding amifostine to 
melatonin when compared with melatonin alone (p 0.243), there is 
statistically significant better protective effect in amifostine plus 
melatonin group when compared with amifostine alone group (p 
0.003). As there was no significant damage following 8 Gy whole body 
irradiation on the kidney tubule, the protective effect of any agent 
could not be assessed. 
 
Table 1. The percentage of damaged glomeruli 
 Groups 
 ContRT RT+AMI RT+MELRT+AMI+MEL 
Glomeruli 
damage (%)
0 40 30 20 20 
0 40 40 20 30 
0 50 40 30 30 
0 40 30 25 30 
0 50 20 20 20 
0 40 30 20 15 
0 40 30 25 20 
0 50 40 30 15 
0 40 40 20 15 
0 40 30 30 20 
 
 
Conclusions: In this study, it has shown that the protective effect of 
melatonin on radiation induced acute renal toxicity is better than 
amifostine. These results are encouraging for the clinical use of 
melatonin. 
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Purpose/Objective: To investigate possible synergetic effects 
between dose to the anal-sphincter region and dose to the rectum for 
the occurrence of long-term fecal leakage after radiation therapy for 
prostate cancer. 
Materials and Methods: For the current analyses we included 414 
prostate-cancer survivors who had received external beam radiation 
therapy (EBRT) to a total dose of 70 Gy in 2 Gy daily fractions 
between 1993 and 2006. We also included 332 population-based 
controls matched for age and residency. EBRT was delivered using one 
anterior–posterior and two lateral wedged field. The planning target 
volume comprised the prostate or post-operative prostatic region with 
20 mm margin except for the rectal margin, which was 15 mm or 
maximum half the rectal cross-sectional area. We restored original 
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treatment plans on which we delineated the anal-sphincter region 
(ASR) and the rectum following the outer border (Figure). We 
delineated the anal-sphincter region extending from the end of the 
rectal ampulla to the anus. The rectum was delineated from the 
recto-sigmoid junction to the end of the rectal ampulla. Fecal leakage 
was assessed in the questionnaire by the question 'Have you had fecal 
leakage while awake, the previous six months?'. The responses were 
dichotomized at a level of symptom occurrence at least once a month. 
 
 Results: Prostate-cancer survivors who reported faecal leakage at 
least once a month had received an average mean dose to the rectum 
of 47.8 Gy compared to 44.0 Gy for those who reported faecal leakage 
less than once a month (two-sided t test p=0.009). When stratifying 
the mean absorbed dose to the rectum in 5 Gy-bins we found a 
statistically significantly higher occurrence of faecal leakage 
compared to population-based controls from 35 Gy and above. Men 
who had received a mean absorbed dose of ≥40 Gy to the anal-
sphincter region (IJROBP 2012;84:e131) and ≥35 Gy to the rectum had 
the highest prevalence ratio 4.6 (95% CI 2.2–9.5) of faecal leakage 
compared to controls (Table). 
 
  
Conclusions: Our results suggest that the combination of dose to the 
anal-sphincter region and dose to the rectum contributes to the 
excess risk of long-term faecal leakage after radiation therapy for 
prostate cancer. These findings indicate that future prediction models 
for this symptom may need to consider both these organs-at-risk.  
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Purpose/Objective: Since the objective of conservative treatment, in 
addition to local control and survival, is the aesthetic result, the 
acute toxicity and cosmetic outcome evaluation is essential. Here we 
present the results of the first 256 breast cancer pts treated with 
HPRT scheme. 
Materials and Methods: Clinical records of 294 breast cancer pts 
receiving postoperative HPRT after conservative surgery pts had been 
evaluated. Age: Mean 57.26 years (range 30-80). Tumor location: 
54.08% (158) of the pts on the right breast and 45.92% (136) on the 
left. Surgical treatment: Lumpectomy+sentinel node technique (181 
pts, 61.56%), quandrantectomy+axillary dissection (60 pts, 20.40%), 
and lumpectomy+axillary dissection (53 pts, 18.04%). Histology: CDI 
(94.89%). Tumor size: 1.39 cm. (range 0.4-5.8). Histological grade: GI 
29.25%, G2 40.81% and G3 29.94%. Resection margins: 18 pts (6.12%) 
with positive margins. Hormone receptors: (-) in 6.46%. HER-2: (-) in 
11.22%. Sentinel lymph node: (+) in 1.70%. Isolated axillary nodes: 
Mean 12.5 (range 1-24). Positive 1.02 (range 0-2). Stage: I 70.06%, II 
27.55%, and III 2.39%. RTP schedule: Breast: 40.5 Gy in 15 fractions of 
2.7 Gy. Boost: 103 pts (35.03%) received no boost, 176 (59.86%) 
received 10 Gy/5fr and 15 (5.11%) received 14 Gy/7fr. Adjuvant 
chemotherapy: 52.38%. Hormone therapy: 58.87%. Follow-up 
schedule: Weekly based during RTP, 1 month after the end of RTP 
and, later, every three months. 
Results: 77 pts (26.19%) developed radiodermatitis. Of these, 88.31% 
Grade I and 11.69% Grade II. The mean dose at which radiodermatitis 
appeared was 34.92 Gy (range 13.5-46.5). After 12 months of follow-
up, only 17 pts (5.78%) had a slight residual hyperpigmentation in the 
treated area. 
Conclusions: With careful planning, acute toxicity and cosmetic 
outcome of HPRT are perfectly comparable to that obtained with 
conventional fractionation. Thus, in addition, this treatment scheme 
reduces total time of treatment and, therefore, a decrease in the 
waiting list is achieved. 
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Purpose/Objective: In breast cancer pts it’s crucial, because of its 
high survival, to study the possibilities of developing a radiation-
induced cancer. In its development are implicated low range radiation 
doses (up to 20 to 30 Gy, depending on the tumor type) received by 
the healthy tissue, except for second sarcoma, induced at higher 
doses. The dose over the entire breast is 50 Gy, and therefore this 
dose is outside the above range. The purpose of this study is to 
analyze the effects of boost performed, whose value is between 10 
and 16 Gy [included within the dosage range previously mentioned as 
potential inducer of second cancers in areas as homolateral (HL) and 
contralateral lung (CL) and breast (CB)] and find out if there is any 
difference if its delivered by PH or E and, therefore, one technique is 
more cancer inductive than the other. We present the results of the 
first five pts. 
Materials and Methods: 5 consecutive breast cancer pts, treated with 
conservative intend, undergoing radiotherapy, were enrolled. The 
Eclipse (Varian) version 10.0 planning system was used for treatment 
planning and dose-volume histograms (DVH) analysis. Statistical 
analysis of data was performed by MATLAB software. For each pt, two 
different boost planning options were calculated; one by PH and 
another by E. DVH of each were analyzed and determined: a) Volume 
(cm3) of HL and CL receiving a dose between 5 and 20 Gy (V5-20 Gy). 
b) Volume (cm3) of CB receiving a dose between 5 and 10 Gy (V5-10 
Gy). c) Volume (cm3) of esophagus receiving a dose between 10 and 20 
Gy (V10-20 Gy). These cancer induction dose ranges had been 
reported by Schneider et al in 2011. Also, the mean integral dose in 
the treated breast (MIDB) and the mean integral dose received in the 
whole simulation volume (MIDWSV) were determined for each patient. 
A Wilcoxon-Mann Whitney test was performed for each organ. 
Results: The Wilcoxon-Mann Whitney test was performed for HL, MIDB 
and MIDWSV because, in the other organs we observed that the 
volumes receiving doses considered limiting were null. The test 
showed that the null hypothesis was true (median equal for both data 
samples, with a significance level of 5%) for HL, but false for MIDB and 
MIDWSV. Therefore, in the group of patients, no significant 
differences were found in HL between both boost treatment 
modalities (PH or E), but they were found for MIDB (increased for E) 
and for MIDWSV (increased for PH). 
Conclusions: There is a significant difference between E or PH boost 
regarding low doses in distant organs. Not differences were found 
regarding lung doses for both techniques. E boost possibly is more 
related to higher probability of homolateral induced sarcoma. Integral 
dose is also higher in PH boost. Integral dose has been linked to 
general cancer induction. This low dose distribution might be used as 
